The Company incurred $0.7 million in restructuring charges in the first quarter of fiscal year 2021, which primarily consisted of employee severance costs.We paid $3.0 million for restructuring charges in the first quarter of fiscal year 2021.Backlog adjustments totaled a net reduction of $88.1 million in the three months ended January 1, 2021, compared to a net reduction of $74.5 million in the year-ago period.By making forward-looking statements, we have not assumed any obligation to, and you should not expect us to, update or revise those statements because of new information, future events or otherwise.To date, we have not experienced a significant decline in customer credit quality or a significant increase in requests for changes or extension of payment terms as a result of COVID-19, although we will continue to closely monitor these metrics going forward.Our Oncology Systems backlog at January 1, 2021 was 1% higher than the backlog at January 3, 2020, which reflected an increase of 7% from our international region, offset by a decrease of 6% from our North America region.We are unable to reliably estimate the timing of the remainder of future payments related to uncertain tax positions; we believe that existing cash and cash equivalents, cash to be generated from operations, and current or future credit facilities will be sufficient to satisfy any payment obligations that may arise related to our liability for uncertain tax positions.Except for the item discussed above, there has been no significant change to the other contractual obligations we reported in our 2020 Annual Report.• The major contributors to the net change in operating assets and liabilities, net of effects of acquisitions, in the three months ended January 1, 2021, were as follows: ◦ Trade and unbilled receivables decreasing $29.1 million, primarily due to higher collections of receivables in Proton Solutions.Management’ s Discussion and Analysis of Financial Condition and Results of OperationsForward-Looking StatementsThis Quarterly Report on Form 10-Q contains“ forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, which provides a“ safe harbor” for statements about future events, products and future financial performance that are based on the beliefs of, estimates made by, and information currently available to the management of the Company.This discussion and analysis of our financial condition and results of operations is based upon and should be read in conjunction with the Condensed Consolidated Financial Statements and the Notes included elsewhere in this Quarterly Report on Form 10-Q and the Consolidated Financial Statements, the Notes to the Consolidated Financial Statements and the related Management’ s Discussion and Analysis of Financial Condition and Results of Operations in the 2020 Annual Report, as well as the information contained under Part I, Item 1A "Risk Factors" of the 2020 Annual Report and Part II, Item 1A "Risk Factors" of this Quarterly Report on Form 10-Q, and other information provided from time to time in our other filings with the SEC.For additional information on risk factors that could impact our results, please refer to“ Risk Factors” in Part I, Item 1A of this Form 10-K. Our ResponseSince the outbreak of the pandemic, our focus has been on keeping our employees safe, supporting our customers and their patients, and ensuring supply chain stability and business continuity.We have implemented stringent safety protocols at all of our manufacturing facilities, including rigorous health and safety training for all manufacturing employees and the institution of new workplace spacing requirements.49 Recent Accounting Standards Adopted or Updates Not Yet EffectiveSee Note 1, "Summary of Significant Accounting Policies," of the Notes to the condensed consolidated financial statements for a description of recent accounting standards, including the expected dates of adoption and the estimated effects on our consolidated financial statements.